The aim of this prospective PK study was to evaluate the pharmacokinetics of ciprofloxacin dosed within the first 36 h (early phase) and after 3 days of treatment (delayed phase) using individual and population PK analysis. The secondary aim of the study was to evaluate possible dosing implications of the observed PK differences between early and delayed phases to achieve a PK/PD target for ciprofloxacin of AUC24/MIC ≥ 125. Blood concentrations of ciprofloxacin (1 and 4 h after dose and trough) were monitored in critically ill adults in the early and delayed phases of the treatment. Individual and population PK analyses were performed. Complete concentration-time profiles in the early phase, delayed phase, and both phases were obtained from 29, 15, and 14 patients, respectively. No systematic changes in ciprofloxacin PK parameters between the early and delayed phases were observed, although variability was higher at the early phase. Both individual and population analyses provided similar results. Simulations showed that after standard dosing, it is practically impossible to reach the recommended ciprofloxacin PK/PD target (AUC/MIC ≥ 125) for pathogens with MIC ≥ 0.5 mg/L. A dosing nomogram utilizing patients' creatinine clearance and MIC values was constructed. Both individual and population analyses provided similar results. Therapeutic drug monitoring should be implemented to safeguard the optimal ciprofloxacin exposure.

Department of Anesthesiology and ICM 2nd Faculty of Medicine Charles University Prague and Motol University Hospital 150 06 Prague Czech Republic

Department of Medical Microbiology 2nd Faculty of Medicine Charles University Prague and Motol University Hospital 150 06 Prague Czech Republic

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague 128 00 Prague Czech Republic

Forensic Laboratory of Biologically Active Substances Department of Chemistry of Natural Compounds University of Chemistry and Technology Prague 166 28 Prague Czech Republic

Zobrazit více v PubMed

Dalhoff A. Global Fluoroquinolone Resistance Epidemiology and Implictions for Clinical use. Interdiscip. Perspect. Infect Dis. 2012;2012 doi: 10.1155/2012/976273. PubMed DOI PMC

Cruciani M., Bassetti D. The Fluoroquinolones as Treatment for Infections Caused by Gram-positive Bacteria. J. Antimicrob. Chemother. 1994;33:403–417. doi: 10.1093/jac/33.3.403. PubMed DOI

Mouton J.W., Muller A.E., Canton R., Giske C.G., Kahlmeter G., Turnidge J. MIC-based Dose Adjustment: Facts and Fables. J. Antimicrob. Chemother. 2018;73:564–568. doi: 10.1093/jac/dkx427. PubMed DOI

Abdulla A., Rogouti O., Hunfeld N.G., Endeman H., Dijkstra A., van Gelder T., Muller A.E., de Winter B.C., Koch B.C. Population Pharmacokinetics and Target Attainment of Ciprofloxacin in Critically Ill Patients. Eur. J. Clin. Pharmacol. 2020;76:957–967. doi: 10.1007/s00228-020-02873-5. PubMed DOI PMC

Khachman D., Conil J.-M., Georges B., Saivin S., Houin G., Toutain P.-L., Laffont C.M. Optimizing Ciprofloxacin Dosing in Intensive Care Unit Patients through the Use of Population Pharmacokinetic–pharmacodynamic Analysis and Monte Carlo Simulations. J. Antimicrob. Chemother. 2011;66:1798–1809. doi: 10.1093/jac/dkr220. PubMed DOI

Van Zanten A.R., Polderman K.H., van Geijlswijk I.M., van der Meer G.Y., Schouten M.A., Girbes A.R. Ciprofloxacin Pharmacokinetics in Critically Ill Patients: A Prospective Cohort Study. J. Crit. Care. 2008;23:422–430. doi: 10.1016/j.jcrc.2007.11.011. PubMed DOI

De Cock R.F., Piana C., Krekels E.H., Danhof M., Allegaert K., Knibbe C.A. The Role of Population PK-PD Modelling in Paediatric Clinical Research. Eur. J. Clin. Pharmacol. 2011;67:5–16. doi: 10.1007/s00228-009-0782-9. PubMed DOI PMC

Leligdowicz A., Matthay M.A. Heterogeneity in Sepsis: New Biological Evidence with Clinical Applications. Crit. Care. 2019;23:1–8. doi: 10.1186/s13054-019-2372-2. PubMed DOI PMC

Roberts J.A., Paul S.K., Akova M., Bassetti M., De Waele J.J., Dimopoulos G., Kaukonen K.-M., Koulenti D., Martin C., Montravers P. DALI: Defining Antibiotic Levels in Intensive Care Unit Patients: Are Current β-Lactam Antibiotic Doses Sufficient for Critically Ill Patients? Clin. Infect. Dis. 2014;58:1072–1083. doi: 10.1093/cid/ciu027. PubMed DOI

Blot S.I., Pea F., Lipman J. The Effect of Pathophysiology on Pharmacokinetics in The Critically Ill Patient—Concepts Appraised by the Example of Antimicrobial Agents. Adv. Drug Deliv. Rev. 2014;77:3–11. doi: 10.1016/j.addr.2014.07.006. PubMed DOI

Traynor J., Mactier R., Geddes C.C., Fox J.G. How to Measure Renal Function in Clinical Practice. BMJ. 2006;333:733–737. doi: 10.1136/bmj.38975.390370.7C. PubMed DOI PMC

Cockcroft D.W., Gault M.H. Prediction of Creatinine Clearance from Serum Creatinine. Nephron. 1976;16:31–41. doi: 10.1159/000180580. PubMed DOI

Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., III, Kusek J.W., Eggers P., Van Lente F., Greene T., et al. A New Equation to Estimate Glomerular Filtration Rate. Ann. Intern. Med. 2009;150:604–612. doi: 10.7326/0003-4819-150-9-200905050-00006. PubMed DOI PMC

Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A More Accurate Method to Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction Equation. Modification of Diet in Renal Disease Study Group. Ann. Intern. Med. 1999;130:461–470. doi: 10.7326/0003-4819-130-6-199903160-00002. PubMed DOI

Nyman U., Grubb A., Larsson A., Hansson L.O., Flodin M., Nordin G., Lindstrom V., Bjork J. The Revised Lund-Malmo GFR Estimating Equation Outperforms MDRD and CKD-EPI Across GFR, Age and BMI Intervals in a Large Swedish Population. Clin. Chem. Lab. Med. 2014;52:815–824. doi: 10.1515/cclm-2013-0741. PubMed DOI

Dubois D., Dubois E.F. Nutrition Metabolism Classic–A Formula to Estimate the Approximate Surface-Area If Height and Weight Be Known (Reprinted from Archives Internal Medicine, Vol 17, Pg 863, 1916) Nutrition. 1989;5:303–313. PubMed

Boer P. Estimated Lean Body Mass as an Index for Normalization of Body Fluid Volumes in Humans. Am. J. Physiol. 1984;247:F632–F636. doi: 10.1152/ajprenal.1984.247.4.F632. PubMed DOI

Drusano G.L., Weir M., Forrest A., Plaisance K., Emm T., Standiford H.C. Pharmacokinetics of Intravenously Administered Ciprofloxacin in Patients with Various Degrees of Renal Function. Antimicrob. Agents Chemother. 1987;31:860–864. doi: 10.1128/AAC.31.6.860. PubMed DOI PMC

Lindbom L., Pihlgren P., Jonsson E.N. PsN-Toolkit--A Collection of Computer Intensive Statistical Methods for Non-Linear Mixed Effect Modeling using NONMEM. Comput. Methods Programs Biomed. 2005;79:241–257. doi: 10.1016/j.cmpb.2005.04.005. PubMed DOI

Lindbom L., Ribbing J., Jonsson E.N. Perl-speaks-NONMEM (PsN)--A Perl Module for NONMEM Related Programming. Comput. Methods Programs Biomed. 2004;75:85–94. doi: 10.1016/j.cmpb.2003.11.003. PubMed DOI

Keizer R.J., van Benten M., Beijnen J.H., Schellens J.H., Huitema A.D. Pirana and PCluster: A Modeling Environment and Cluster Infrastructure for NONMEM. Comput. Methods Programs Biomed. 2011;101:72–79. doi: 10.1016/j.cmpb.2010.04.018. PubMed DOI

Comets E., Brendel K., Mentré F. Computing Normalised Prediction Distribution Errors to Evaluate Nonlinear Mixed-effect Models: The Npde Add-on Package for R. Comput. Methods Programs Biomed. 2008;90:154–166. doi: 10.1016/j.cmpb.2007.12.002. PubMed DOI

Byon W., Smith M.K., Chan P., Tortorici M.A., Riley S., Dai H., Dong J., Ruiz-Garcia A., Sweeney K., Cronenberger C. Establishing Best Practices and Guidance in Population Modeling: An Experience with an Internal Population Pharmacokinetic Analysis Guidance. CPT Pharmacomet. Syst. Pharmacol. 2013;2:e51. doi: 10.1038/psp.2013.26. PubMed DOI PMC

Boucher B.A., Wood G.C., Swanson J.M. Pharmacokinetic Changes in Critical Illness. Crit. Care Clin. 2006;22:255–271. doi: 10.1016/j.ccc.2006.02.011. PubMed DOI

Abdul-Aziz M.H., Alffenaar J.C., Bassetti M., Bracht H., Dimopoulos G., Marriott D., Neely M.N., Paiva J.A., Pea F., Sjovall F., et al. Antimicrobial Therapeutic Drug Monitoring in Critically Ill Adult Patients: A Position Paper. Intensive Care Med. 2020;46:1127–1153. doi: 10.1007/s00134-020-06050-1. PubMed DOI PMC

Roberts J.A., Alobaid A.S., Wallis S.C., Perner A., Lipman J., Sjövall F. Defining Optimal Dosing of Ciprofloxacin in Patients with Septic Shock. J. Antimicrob. Chemother. 2019;74:1662–1669. doi: 10.1093/jac/dkz069. PubMed DOI

De Velde F., Mouton J.W., de Winter B.C.M., van Gelder T., Koch B.C.P. Clinical Applications of Population Pharmacokinetic Models of Antibiotics: Challenges and Perspectives. Pharmacol Res. 2018;134:280–288. doi: 10.1016/j.phrs.2018.07.005. PubMed DOI

Alobaid A.S., Hites M., Lipman J., Taccone F.S., Roberts J.A. Effect of Obesity on The Pharmacokinetics of Antimicrobials in Critically Ill Patients: A Structured Review. Int. J. Antimicrob. Agents. 2016;47:259–268. doi: 10.1016/j.ijantimicag.2016.01.009. PubMed DOI

Sima M., Hartinger J., Cikankova T., Slanar O. Estimation of Once-daily Amikacin Dose in Critically Ill Adults. J. Chemother. 2018;30:37–43. doi: 10.1080/1120009X.2017.1376818. PubMed DOI

Sima M., Hartinger J., Stenglova Netikova I., Slanar O. Creatinine Clearance Estimations for Vancomycin Maintenance Dose Adjustments. Am. J. Ther. 2018;25:e602–e604. doi: 10.1097/MJT.0000000000000616. PubMed DOI

Fabre D., Bressolle F., Gomeni R., Arich C., Lemesle F., Beziau H., Galtier M. Steady-state Pharmacokinetics of Ciprofloxacin in Plasma from Patients with Nosocomial Pneumonia: Penetration of The Bronchial Mucosa. Antimicrob. Agents Chemother. 1991;35:2521–2525. doi: 10.1128/AAC.35.12.2521. PubMed DOI PMC

Gasser T.C., Ebert S.C., Graversen P.H., Madsen P.O. Ciprofloxacin Pharmacokinetics in Patients with Normal and Impaired Renal Function. Antimicrob. Agents Chemother. 1987;31:709–712. doi: 10.1128/AAC.31.5.709. PubMed DOI PMC

Webb D.B., Roberts D.E., Williams J.D., Asscher A.W. Pharmacokinetics of Ciprofloxacin in Healthy Volunteers and Patients with Impaired Kidney Function. J. Antimicrob. Chemother. 1986;18:83–87. doi: 10.1093/jac/18.Supplement_D.83. PubMed DOI

Wingender W., Graefe K.H., Gau W., Forster D., Beermann D., Schacht P. Pharmacokinetics of Ciprofloxacin After Oral and Intravenous Administration in Healthy Volunteers. Eur. J. Clin. Microbiol. 1984;3:355–359. doi: 10.1007/BF01977494. PubMed DOI

Factors Affecting the Metabolic Conversion of Ciprofloxacin and Exposure to Its Main Active Metabolites in Critically Ill Patients: Population Pharmacokinetic Analysis of Desethylene Ciprofloxacin